₹ 2.2 Cr
Volume Transacted
(Nov 22, 2024)
18.1 K
Stocks Traded
(Nov 22, 2024)
Last Updated on: Nov 24, 2024
Dr Reddys Laboratories Ltd
NSE: DRREDDY
EPS
₹ 63.98
Last updated on: Nov 22, 2024
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Historical Earning per Share of Dr Reddys Laboratories Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
No data available
* All values are in ₹
Market Cap
₹ 101,285 Cr
EPS
₹ 64.0
P/E Ratio (TTM) *
19.0
P/B Ratio (TTM) *
3.3
Day’s High *
1222.85
Day’s Low
₹ 1194.0
DTE *
0.2
ROE *
17.4
52 Week High
₹ 1420.2
52 Week Low
₹ 1074.35
ROCE *
20.7
* All values are consolidated
Last Updated time: 24 Nov 11:40 AM
* All values are consolidated
Last Updated time: 24 Nov 11:40 AM
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
Date | Price (₹) | Day Open (₹) | Day High (₹) | Day Low (₹) |
---|
22 Nov 2024 | 1213.9 | 1195.05 | 1222.85 | 1194 |
21 Nov 2024 | 1194.55 | 1175.05 | 1207.2 | 1175 |
19 Nov 2024 | 1213.95 | 1191.05 | 1231.75 | 1187.2 |
18 Nov 2024 | 1193.35 | 1195.6 | 1221 | 1171 |
14 Nov 2024 | 1226.05 | 1254.55 | 1254.55 | 1222.25 |
13 Nov 2024 | 1245.7 | 1259.3 | 1263.5 | 1239 |
12 Nov 2024 | 1263.1 | 1288 | 1288.2 | 1257 |
11 Nov 2024 | 1288.2 | 1299.45 | 1299.45 | 1263.35 |
08 Nov 2024 | 1281.85 | 1288.8 | 1290 | 1259.6 |
07 Nov 2024 | 1287.15 | 1304.05 | 1311.6 | 1281 |
Date | Price (₹) |
---|---|
22 Nov 2024 | 1213.9 |
21 Nov 2024 | 1194.55 |
19 Nov 2024 | 1213.95 |
18 Nov 2024 | 1193.35 |
14 Nov 2024 | 1226.05 |
13 Nov 2024 | 1245.7 |
12 Nov 2024 | 1263.1 |
11 Nov 2024 | 1288.2 |
08 Nov 2024 | 1281.85 |
07 Nov 2024 | 1287.15 |
Strength
2
S
Weakness
2
W
Opportunity
0
O
Threats
1
T
Revenue
Profitability
Affordability
Liquidity
Dividend
Market Value
₹ 1,01,286
Asset Value
₹ 21,458
3.7 X
Value addition
* All values are in Rupees
Company Name | EPS | Market Cap (INR Cr.) |
---|---|---|
Dr Reddys Laboratories Ltd | 63 | 1,01,285 |
Sun Pharmaceuticals Industries Ltd | 46 | 4,31,352 |
Divis Laboratories Ltd | 69 | 1,59,265 |
Cipla Ltd | 57 | 1,20,033 |
Torrent Pharmaceuticals Ltd | 51 | 1,07,301 |
Mankind Pharma Ltd | 52 | 1,02,231 |
Historical Market Cap of Dr Reddys Laboratories Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
No data available
* All values are in ₹ crore
Historical Revenue of Dr Reddys Laboratories Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
No data available
* All values are in ₹ crore
Historical EBITDA of Dr Reddys Laboratories Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
No data available
* All values are in ₹ crore
Historical Net Profit of Dr Reddys Laboratories Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
No data available
* All values are in ₹ crore
No data available
DRL slips after Hyderabad facility gets 7 observations from USFDA
The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issu...
21 Nov 202410:23
DRL's Hyderabad facility gets 7 observations from USFDA
The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issu...
20 Nov 202410:40
Mexican health regulator imposes penalty on Dr Reddy's
Dr Reddys Laboratories has received an order dated 12 November 2024, from COFEPRIS (Comisi...
14 Nov 202409:22
Dr Reddys Laboratories Ltd spurts 2.25%
Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoti...
06 Nov 202413:05
Dr Reddy's Q2 PAT slides 15% YoY to Rs 1,255 crore
Total revenue from operations stood at Rs 8,038.2 crore in Q2 FY25, up 16.45% YoY, primari...
05 Nov 202417:35
Aurigene Oncology receives nod for Phase 2 clinical trial for Ribrecabtagene autoleucel
Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the...
08 Oct 202418:16
Concalls
Aug 2024
TranscriptJuly 2024
TranscriptMay 2024
TranscriptFeb 2024
TranscriptNov 2023
TranscriptMay 2023
TranscriptJan 2023
TranscriptNov 2022
TranscriptFeb 2022
TranscriptNov 2021
TranscriptAug 2021
TranscriptMay 2021
TranscriptMay 2020
TranscriptJan 2020
TranscriptAug 2024
TranscriptJuly 2024
TranscriptMay 2024
TranscriptFeb 2024
TranscriptNov 2023
TranscriptMay 2023
TranscriptJan 2023
TranscriptNov 2022
TranscriptFeb 2022
TranscriptNov 2021
TranscriptAug 2021
TranscriptMay 2021
TranscriptMay 2020
TranscriptJan 2020
TranscriptUnlimited trading at just
Rs. 199*